Health Canada Approves Lynparza in Combination with Abiraterone and Prednisone or Prednisolone for Patients with BRCA Mutated Metastatic Castration-Resistant Prostate Cancer

Health Canada has granted conditional approval for the use of Lynparza in combination with abiraterone and prednisone or prednisolone to treat patients with BRCA mutated metastatic castration-resistant prostate cancer. This exciting development is based on the promising results from the Phase 3 PROpel trial, which demonstrated that patients receiving Lynparza/abiraterone experienced improved rad..